Humacyte, Inc. (HUMA) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 10 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for HUMA is $4.50, representing a +511.3% upside from the current price of $0.7361. Price targets range from a low of $3.00 to a high of $6.00.
